Quick Answer
Yes, Medicare Part B covers Monovisc injections for knee osteoarthritis when medical necessity criteria are met. Monovisc is a single-injection viscosupplement, meaning you only need one office visit per treatment course. Most patients pay 20% coinsurance after meeting their Part B deductible.
Medicare Part B Coverage for Monovisc
Monovisc is a cross-linked sodium hyaluronate injection manufactured by DePuy Synthes (a Johnson & Johnson company). Its single-injection design makes it one of the most convenient viscosupplementation options. Medicare covers Monovisc under Part B (the medical benefit) because it is administered by a healthcare provider in a clinical setting.
Key coverage facts:
- Covered under Part B as a physician-administered injectable
- No prior authorization required under Original Medicare
- Subject to Local Coverage Determinations (LCDs) from your regional MAC
- Must meet medical necessity criteria documented in your medical records
- Single injection means only one office visit per treatment course
Coverage Requirements
Medical Necessity Criteria
For Medicare to pay for Monovisc, your medical records must show:
- Diagnosis of knee osteoarthritis with ICD-10 code M17.x
- Failure of conservative treatment for at least 3 months, including physical therapy, NSAIDs, or activity modification
- Chart documentation showing conservative approaches were not adequate
- X-ray evidence confirming osteoarthritis (most MACs require imaging within the past 12 months)
Billing Codes
| Code | Description | 2026 Estimated Allowable |
|---|---|---|
| J7327 | Monovisc (hyaluronan), per dose | $600 - $800 |
| 20610 | Arthrocentesis, large joint (knee) | $85 - $110 |
| 77002 | Fluoroscopic guidance (if used) | $75 - $95 |
Your provider bills Medicare using J-code J7327 for Monovisc. Since it is a single injection, the J-code is billed once per treatment course.
Frequency Limits
- Medicare typically covers one Monovisc injection per knee every 6 months
- Some MACs allow repeat treatment after 6 months if the initial injection provided meaningful relief
- Bilateral knee treatment (both knees in one visit) is generally covered when both knees have documented OA
- Your provider should document clinical response to justify repeat treatment
Your Out-of-Pocket Costs
| Item | Amount |
|---|---|
| Part B deductible (2026) | $257/year |
| Coinsurance | 20% of Medicare-approved amount |
| Typical total patient cost | $120 - $180 per injection |
| With Medigap | May cover the 20% coinsurance |
Example Cost Calculation
If Medicare approves $700 for a Monovisc injection:
- Medicare pays: $560 (80%)
- You pay: $140 (20%)
- If you have a Medigap plan: your supplement may cover some or all of that $140
Medicare Advantage Plans
If you have a Medicare Advantage (Part C) plan:
- Coverage generally follows Original Medicare guidelines
- Prior authorization may be required — verify with your plan before scheduling
- Copays vary by plan and may differ from the standard 20% coinsurance
- Network restrictions may apply — confirm your provider is in-network
- Contact your plan’s member services for coverage details before your visit
What If Medicare Denies Coverage?
If your Monovisc claim is denied:
- Request the denial reason in writing
- Gather supporting documents including X-rays, treatment records, and a letter of medical necessity from your provider
- File a redetermination (Level 1 appeal) within 120 days
- Include clinical evidence showing that Monovisc is medically necessary for your condition
Many initial denials are overturned on appeal with proper documentation.
Monovisc Product Details
| Feature | Detail |
|---|---|
| Manufacturer | DePuy Synthes (Johnson & Johnson) |
| Active ingredient | Cross-linked sodium hyaluronate |
| Injection schedule | 1 injection per treatment course |
| FDA-approved for | Knee osteoarthritis |
| Molecular weight | High (cross-linked for extended residence time) |
| Source | Avian-derived (chicken comb extract) |
| Volume per injection | 4 mL |
Monovisc uses cross-linking technology to create a gel-like substance that stays in the joint longer than non-cross-linked HA products. The cross-linking process helps the hyaluronic acid resist breakdown, potentially extending the duration of relief compared to standard formulations.
Frequently Asked Questions
How often will Medicare pay for Monovisc?
Medicare generally covers one Monovisc injection per knee every 6 months. Your provider must document medical necessity each time and that the prior injection provided clinical benefit.
Do I need prior authorization for Monovisc under Medicare?
No. Original Medicare does not require prior authorization for Monovisc. Medicare Advantage plans may have their own prior authorization requirements. Always verify with your plan before scheduling.
Is Monovisc covered under Medicare Advantage?
Yes. Medicare Advantage plans must cover everything Original Medicare covers. Your plan may have different cost-sharing, network requirements, or prior authorization rules. Contact your plan for specific details.
What is the difference between Monovisc and Orthovisc?
Both products are made by DePuy Synthes. Monovisc is a single injection using cross-linked HA, while Orthovisc requires 3 to 4 weekly injections with non-cross-linked HA. Monovisc offers the convenience of one office visit. Your provider can help determine which is better for your situation. Medicare covers both.
Does Monovisc contain animal products?
Yes. Monovisc is derived from chicken combs. If you have allergies to poultry, feathers, or eggs, inform your doctor before treatment. Non-avian alternatives like Euflexxa are available and also covered by Medicare.